Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...

For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...